OGD ‘Attack’ Team Reviewing Supplements for Shorted Drugs

In an effort to reduce the backlog of ANDA supplements, a review team within CDER’s Office of Generic Drugs (OGD) this month will start reviewing all backlogged supplements for drugs currently on the FDA’s shortages list.
Generic Line